Disrupting Leukemia's Deadly Reliance on Vitamin B6: Study

by Iswarya on  January 14, 2020 at 1:14 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

New study may have found a way to stop the growth of Acute Myeloid Leukemia (AML); cancer which relies on vitamin B6 to survive, so preventing B6 from aiding in the creation of new cells may be a way to halt cancer without hurting healthy cells, reports a new study. The findings of the study are published in the journalCancer Cell.
Disrupting Leukemia's Deadly Reliance on Vitamin B6: Study
Disrupting Leukemia's Deadly Reliance on Vitamin B6: Study

That's because, like many other deadly cancers, the cells involved in this aggressive form of blood cancer can divide and spread faster than most treatments can kill them.

Show Full Article


CSHL Fellow Lingbo Zhang wanted to know how AML can achieve such rapid growth, so he looked closely at the genes of the disease's cancerous white blood cells.

"We found more than 230 genes that are very active in leukemic cells, and then we tested them, one by one," he explained.

Using CRISPR gene-editing technology, Zhang's lab shut down the activity of each of these 230 suspect genes to see if their absence would stop the cancer cells from proliferating. Among the hundreds of genes they tested, one pattern emerged. The gene which produces PDXK, the enzyme that helps cells use vitamin B6, proved most important for the growth of cancer.

Scott Lowe, a former CSHL fellow and currently the chair of the Cancer Biology and Genetics Program at MSK, said: "While the action of certain vitamins has previously been linked to cancer, the specific links between vitamin B6 identified here were unexpected."

The B6 vitamin is crucial to cell metabolism, producing energy, and other resources important for cell growth. In a healthy cell, the PDXK enzyme manages the activity of B6, making sure that the vitamin does the job when needed. Because normal cells don't actually divide all the time, the PDXK enzyme isn't always pushing the B6 vitamin to be active. It's a different dynamic in cancer cells, which divide more frequently than normal cells. In AML cells, Zhang saw that the PDXK enzyme was always pushing B6 activity.

What this shows is that "leukemic cells are addicted to vitamin B6," he said. "You can call it a vulnerability of cancer."

Zhang cautions that his research on how cancer cells use the B6 vitamin to proliferate does not mean that cancer patients would necessarily benefit from the reduced intake of B6 vitamin as part of their diet. The B6 vitamin is necessary for the survival of healthy cells. Zhang's research shows that cancer cells take advantage of the PDXK enzyme to increase B6 vitamin activity. This increased activity fuels AML growth.

Zhang and his colleagues say the next step is to develop a drug that specifically blocks leukemia from activating the PDXK enzyme. By manipulating the way the enzyme manages the activity of B6, a drug could slow or even stop the growth of cancerous cells without the profound side effects that would result from completely eliminating B6 from healthy cells. With the help of medicinal chemists, the team is now exploring this route.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive